BlueCross BlueShield
Federal Employee Program

BRUKINSA
(zanubrutinib)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Mantle cell lymphoma (MCL)
    a. Patient has received at least one prior therapy
2. Waldenström's macroglobulinemia (WM)
3. Relapsed or refractory marginal zone lymphoma (MZL)
    a. Patient has received at least one anti-CD20-based regimen
4. Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
5. Relapsed or refractory follicular lymphoma (FL)
    a. Patient has received two or more lines of systemic therapy
    b. Used in combination with Gazyva (obinutuzumab)

AND ALL of the following:

a. Prescriber agrees to monitor for bleeding and malignancies
b. Prescriber agrees to monitor CBC for cytopenias
c. Prescriber agrees to monitor for cardiac arrhythmias
d. Females of reproductive potential **only**: patient will be advised not to become pregnant during treatment with Brukinsa and for at least 1 week after the last dose
e. Males with female partners of reproductive potential **only**: patient will be advised not to father a child during treatment with Brukinsa and for at least 1 week after the last dose

Prior - Approval Limits

Quantity 360 capsules per 90 days

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

BRUKINSA
(zanubrutinib)

Diagnoses

Patient must have **ONE** of the following:

1. Mantle cell lymphoma (MCL)
2. Waldenström's macroglobulinemia (WM)
3. Relapsed or refractory marginal zone lymphoma (MZL)
4. Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
5. Relapsed or refractory follicular lymphoma (FL)
    a. Used in combination with Gazyva (obinutuzumab)

AND ALL of the following:

a. **NO** disease progression or unacceptable toxicity
b. Prescriber agrees to monitor for bleeding and malignancies
c. Prescriber agrees to monitor CBC for cytopenias
d. Prescriber agrees to monitor for cardiac arrhythmias
e. Females of reproductive potential **only**: patient will be advised not to become pregnant during treatment with Brukinsa and for at least 1 week after the last dose
f. Males with female partners of reproductive potential **only**: patient will be advised not to father a child during treatment with Brukinsa and for at least 1 week after the last dose

Prior - Approval *Renewal* Limits

Same as above